Quick Answer
Werewolf Therapeutics, Inc. reported Research And Development Expense of $44.83 million for the year ending 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -20.6% in Research And Development Expense from 2024 to 2025.
- This data is from Werewolf Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Werewolf Therapeutics, Inc.'s Research And Development Expense has grown by 169.4%.
- Historical annual values: Fiscal year 2025: $44.83 million | Fiscal year 2024: $56.43 million | Fiscal year 2023: $41.78 million | Fiscal year 2022: $53.76 million | Fiscal year 2021: $35.27 million | Fiscal year 2020: $16.64 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: